Marcelo Sobral-Leite

Marcelo Sobral-Leite

Auto-generated profile, based on publicly available information

Marcelo Sobral-Leite

Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2018 in OncoImmunology
Verified
Journal Article
Closed access
MSMarcelo Sobral-Leite
Marcelo Sobral-Leite
KVKoen Van de Vijver
Koen Van de Vijver
MMMagali Michaut
Magali Michaut
RLRianne van der Linden
Rianne van der Linden
GHGerrit K.J. Hooijer
Gerrit K.J. Hooijer
Marjanka SchmidtMarjanka Schmidt
Marjanka Schmidt
To better understand the expression pattern of programmed death-ligand 1 (PD-L1) expression in different breast cancer types, we characterized PD-L1 expression in tumor and tumor-infiltrating immune cells, in relation to mutation rate, BRCA1-like status and survival. We analyzed 410 primary treatment-naive breast tumors comprising 162 estrogen receptor-positive (ER+) and HER2−, 101 HER2+ and 147 triple-negative (TN) cancers. Pathologists quantified tumor-infiltrating lymphocytes (TILs) and PD-L1 expression in tumor cells and TILs using whole slides and tissue microarray. Mutation rate was assessed by DNA sequencing, BRCA1-like status using multiplex ligation-dependent probe amplification, and immune landscape by multiplex image analyses of CD4, CD68, CD8, FOXP3, cytokeratin, and PD-L1. Half of PD-L1 scores evaluated by tissue microarray were false negatives compared to whole slide evaluations. We observed at least 1% of PD-L1-positive (PD-L1+) cells in 53.1% of ER+HER2−, 73.3% of HER2+, and 84.4% of TN tumors. PD-L1 expression was higher in ductal compared to lobular carcinomas, also within ER+HER2− tumors (p = 0.04). High PD-L1+ TILs score (> 50%) was independently associated with better outcome in TN tumors (HR = 0.27; 95%CI = 0.10–0.69). Within TN tumors, PD-L1 and TIL scores showed a modest but significant positive association with the number of silent mutations, but no association with BRCA1-like status. Multiplex image analyses indicated that PD-L1 is expressed on multiple immune cells (CD68+ macrophages, CD4+, FOXP3+, and CD8+ T cells) in the breast tumor microenvironment, independent of the PD-L1 status of the tumor cells. We found no evidence that levels of PD-L1+ TILs in TN breast cancer are driven by high mutation rate or BRCA1-like status.

9 August 2017 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TRToni Roeke
Toni Roeke
MSMarcelo Sobral-Leite
Marcelo Sobral-Leite
TDTim J. A. Dekker
Tim J. A. Dekker
JWJelle Wesseling
Jelle Wesseling
VSVincent T. H. B. M. Smit
Vincent T. H. B. M. Smit
WMWilma Mesker
Wilma Mesker

2 July 2015 in BMC Medicine
Verified
Journal Article
Open access
PDF file
MSMarcelo Sobral-Leite
Marcelo Sobral-Leite
JWJelle Wesseling
Jelle Wesseling
VSVincentius Smit
Vincentius Smit
HNHeli Nevanlinna
Heli Nevanlinna
MMMartine H. van Miltenburg
Martine H. van Miltenburg
Marjanka SchmidtMarjanka Schmidt
Marjanka Schmidt
Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients. Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical staining in tumor cells. Survival analyses were performed using a multivariable Cox model. The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P <0.0001. ANXA1 was also highly expressed in BCAC tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age. In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS) than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05–1.73), but the association weakened after 10 years (HRadj = 1.13; 95 % CI = 0.91–1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS: HRadj = 1.70; 95 % CI = 1.17–2.45). ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.

1 June 2017 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
JDJoão Marcos de Azevedo Delou
João Marcos de Azevedo Delou
GVGiselle Maria Vignal
Giselle Maria Vignal
VÍVanessa Índio-Do-Brasil
Vanessa Índio-Do-Brasil
MAMaria Theresa de Souza Accioly
Maria Theresa de Souza Accioly
TSTaiana Sousa Lopes da Silva
Taiana Sousa Lopes da Silva
RVRosane Vianna-Jorge
Rosane Vianna-Jorge
ABCB1 gene encodes an adenosine 5’-triphosphate–binding cassette transporter, which not only confers multidrug resistance phenotype in malignant cells, but is also present in several nonmalignant tissues. For the last thirty years, ABCB1 expression in breast cancer has been described by many authors, but the extent of expression differs among the studies, and there is no consensus regarding its potential role in carcinogenesis or in the tumor response to antineoplastic drugs. This study aimed to characterize the expression of ABCB1 in breast tumors as a function of genetic, clinical, and histopathological variables. The ABCB1 expression was also evaluated in nonmalignant mammary tissues adjacent to tumors and in benign lesions. The detection of ABCB1 protein was performed by immunohistochemistry in tissue specimens of excised breasts obtained from a prospective cohort of Brazilian women with breast cancer. The association of ABCB1 protein levels with ABCB1 mRNA, gene polymorphisms, and clinical and histopathological variables was also evaluated. The Kaplan–Meier curves and multivariate Cox regression analyses were conducted to identify independent predictors of disease-free survival of patients with breast cancer. ABCB1 was detected in 86.3% (656) of breast tumors, 98.8% (606) of nonmalignant mammary tissue adjacent to tumors, and 100% (28) of benign lesions. Reduced ABCB1 protein levels in breast tumors was associated with triple-negative subtype (adjusted odds ratio [ORadj] =0.24; 95% confidence interval [CI] =0.13–0.45), lymph node status < pN2 (ORadj =0.27; 95% CI =0.10–0.71), tumor size >2 cm (ORadj =0.55; 95% CI =0.32–0.93), and hypertensive status (ORadj =0.42; 95% CI =0.24–0.73), and it was significantly associated with shorter disease-free survival, either for all breast cancer patients (p log-rank =0.012; hazard ratio [HR] =3.46; 95% CI =1.21–9.91) or for those with triple-negative tumors (p log-rank =0.007; HR =11.41; 95% CI =1.29–100.67). The loss of constitutive ABCB1 expression in breast cancer, especially in triple-negative tumors, seems to indicate a subgroup of worse prognosis.

8 April 2016 in Cancer Biology & Therapy
Verified
Journal Article
Open access
HVHayra de Andrade Vieira-Monteiro
Hayra de Andrade Vieira-Monteiro
DFDaniely Regina Freitas-Alves
Daniely Regina Freitas-Alves
MSMarcelo Sobral-Leite
Marcelo Sobral-Leite
JDJoão Marcos de Azevedo Delou
João Marcos de Azevedo Delou
SGSheyla Maria Torres Goulart-Citrangulo
Sheyla Maria Torres Goulart-Citrangulo
RVRosane Vianna-Jorge
Rosane Vianna-Jorge
Vascular Endothelial Growth Factor (VEGF) mediates angiogenesis, which is crucial for tumor development and progression. The present study aimed to evaluate the impact of VEGFA gene polymorphisms rs699947, rs833061, rs1570360, rs2010963 and rs3025039 on breast cancer features and prognosis. A cohort of Brazilian women (N = 1038) with unilateral non-metastatic breast cancer was evaluated. The association between VEGFA polymorphisms and histopathological features or pathological complete response (pCR) to neoadjuvant chemotherapy was evaluated by the Chi-square test, with calculation of the respective odds ratio (OR) and 95% confidence intervals (95% CI). The impact of individual categories on disease-free survival was evaluated using Kaplan-Meier curves and multivariate Cox proportional hazards regression models for calculation of adjusted hazard ratios (HRadjusted). Variant genotypes of rs699947 (CA + AA) were significantly associated with high-grade (G2 + G3) tumors (OR = 1.82; 95% CI = 1.15 – 2.89), and with shorter disease-free survival among patients treated with neoadjuvant chemotherapy followed by mastectomy (HRadjusted = 1.82; 95% CI = 1.16 – 2.86). Variant genotypes of rs833061 (TC + CC) were significantly associated with high-grade (G2 + G3) tumors (OR = 1.79; 95% CI = 1.12 – 2.84) and with positive lymph node status (OR = 1.34; 95% CI = 1.01 – 1.77), but showed no independent effect on disease-free survival. Variant haplotypes (*2 to *5) appear to favor pCR (OR = 7.1; 95% CI = 1.7 – 30.1). VEGFA genotyping may add to prognostic evaluation of breast cancer, with rs699947 being the most likely to contribute.

14 March 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MLMarcelo Sobral Leite
Marcelo Sobral Leite
LGLetícia Carlos Giacomin
Letícia Carlos Giacomin
DPDiogo Nascimento Piranda
Diogo Nascimento Piranda
JFJuliana Simões Festa-Vasconcellos
Juliana Simões Festa-Vasconcellos
VIVanessa Indio-Do-Brasil
Vanessa Indio-Do-Brasil
RVRosane Vianna-Jorge
Rosane Vianna-Jorge
The epidermal growth factor receptor (EGFR) is differently expressed in breast cancer, and its presence may favor cancer progression. We hypothesized that two EGFR functional polymorphisms, a (CA)n repeat in intron 1, and a single nucleotide polymorphism, R497K, may affect EGFR expression and breast cancer clinical profile.